Welcome to LookChem.com Sign In|Join Free
  • or
rac 4-(3-Aminobutyl)phenol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

52846-75-0

Post Buying Request

52846-75-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

52846-75-0 Usage

Uses

A metabolite of the antihypertensive agent, Labetalol (L096500).

Check Digit Verification of cas no

The CAS Registry Mumber 52846-75-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,8,4 and 6 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 52846-75:
(7*5)+(6*2)+(5*8)+(4*4)+(3*6)+(2*7)+(1*5)=140
140 % 10 = 0
So 52846-75-0 is a valid CAS Registry Number.

52846-75-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(3-Aminobutyl)phenol

1.2 Other means of identification

Product number -
Other names p-hydroxyhomoamphetamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:52846-75-0 SDS

52846-75-0Synthetic route

4-(4-hydroxyphenyl)-2-oxobutane
5471-51-2

4-(4-hydroxyphenyl)-2-oxobutane

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

Conditions
ConditionsYield
With nickel(II) tetrafluoroborate hexahydrate; ammonia; hydrogen; bis(2-diphenylphosphinoethyl)phenylphosphine In 2,2,2-trifluoroethanol at 120℃; for 24h; chemoselective reaction;93%
With ammonia; hydrogen In tetrahydrofuran at 120℃; for 15h;89%
With palladium 10% on activated carbon; ammonium formate In methanol for 5h;
(+)-(R)-1-Methyl-3-(4-methoxyphenyl)-1-propylamine
51062-15-8

(+)-(R)-1-Methyl-3-(4-methoxyphenyl)-1-propylamine

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

Conditions
ConditionsYield
With hydrogen bromide
4-oxy-benzylacetone oxime

4-oxy-benzylacetone oxime

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

Conditions
ConditionsYield
With sodium amalgam; acetic acid at 50 - 60℃;
[((E)-4-(4-methoxyphenyl)but-3-en-2-ylidene)amino]hydroxide
1222558-29-3

[((E)-4-(4-methoxyphenyl)but-3-en-2-ylidene)amino]hydroxide

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: H2 / PtO2 / methanol / 6 h / 60 °C / 15200 Torr
2: HBr
View Scheme
4-(4'-hydroxyphenyl)but-3-en-2-one
22214-30-8, 59417-71-9, 3160-35-8

4-(4'-hydroxyphenyl)but-3-en-2-one

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: palladium 10% on activated carbon; hydrogen / ethanol / 1 h / 20 °C / 1520.1 Torr
2: palladium 10% on activated carbon; ammonium formate / methanol / 5 h
View Scheme
4-hydroxy-benzaldehyde
123-08-0

4-hydroxy-benzaldehyde

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: sodium hydroxide / water / 2 h / 20 °C
2: palladium 10% on activated carbon; hydrogen / ethanol / 1 h / 20 °C / 1520.1 Torr
3: palladium 10% on activated carbon; ammonium formate / methanol / 5 h
View Scheme
C18H13NO4

C18H13NO4

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

8-hydroxy-5-(1-hydroxy-2-((4-(4-hydroxyphenyl)butan-2-yl)amino)ethyl)quinolin-2(1H)-one hydrochloride

8-hydroxy-5-(1-hydroxy-2-((4-(4-hydroxyphenyl)butan-2-yl)amino)ethyl)quinolin-2(1H)-one hydrochloride

Conditions
ConditionsYield
Stage #1: C18H13NO4; p-hydroxyhomoamphetamine With sodium tetrahydroborate In methanol; dimethyl sulfoxide for 1h;
Stage #2: With 5%-palladium/activated carbon; hydrogen In methanol for 1h;
Stage #3: With hydrogenchloride In ethyl acetate for 2h;
94%
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

acetic anhydride
108-24-7

acetic anhydride

A

N-[3-(4-hydroxyphenyl)-1-methylpropyl]acetamide
1204483-45-3

N-[3-(4-hydroxyphenyl)-1-methylpropyl]acetamide

B

4-(3-acetylaminobutyl)phenyl acetate
1204484-14-9

4-(3-acetylaminobutyl)phenyl acetate

Conditions
ConditionsYield
With triethylamine In ethyl acetate at 0℃; for 1h;A 74%
B 7%
3-methyl-5-(2-oxiranylmethoxy-styryl)-isoxazole
79798-34-8

3-methyl-5-(2-oxiranylmethoxy-styryl)-isoxazole

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

4-[3-(2-Hydroxy-3-{2-[(E)-2-(3-methyl-isoxazol-5-yl)-vinyl]-phenoxy}-propylamino)-butyl]-phenol
78351-27-6

4-[3-(2-Hydroxy-3-{2-[(E)-2-(3-methyl-isoxazol-5-yl)-vinyl]-phenoxy}-propylamino)-butyl]-phenol

Conditions
ConditionsYield
In ethanol 1.) reflux, 1 h, 2.) 25 deg C, overnight;30%
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

2,4,6-triphenylpyrylium tetrafluoroborate
448-61-3

2,4,6-triphenylpyrylium tetrafluoroborate

C33H30NO(1+)*BF4(1-)

C33H30NO(1+)*BF4(1-)

Conditions
ConditionsYield
Stage #1: p-hydroxyhomoamphetamine With acetic acid In dichloromethane at 20℃;
Stage #2: 2,4,6-triphenylpyrylium tetrafluoroborate In dichloromethane at 20℃; for 6h;
22%
In ethanol at 80 - 85℃; for 4h;
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

1-[2-(cyclopropyl-methoxy)-ethyl]-4-(2,3-epoxypropoxy)-benzene
63659-17-6

1-[2-(cyclopropyl-methoxy)-ethyl]-4-(2,3-epoxypropoxy)-benzene

4-(3-{3-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-2-hydroxy-propylamino}-butyl)-phenol; hydrochloride

4-(3-{3-[4-(2-Cyclopropylmethoxy-ethyl)-phenoxy]-2-hydroxy-propylamino}-butyl)-phenol; hydrochloride

Conditions
ConditionsYield
With hydrogenchloride In ethanol for 12h; Heating;19%
3,4-dimethoxyphenylacetone
776-99-8

3,4-dimethoxyphenylacetone

p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

4-{3-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamino]-butyl}-phenol

4-{3-[2-(3,4-dimethoxy-phenyl)-1-methyl-ethylamino]-butyl}-phenol

Conditions
ConditionsYield
With formic acid
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

[3-(4-hydroxy-phenyl)-1-methyl-propyl]-urea

[3-(4-hydroxy-phenyl)-1-methyl-propyl]-urea

Conditions
ConditionsYield
With hydrogenchloride; potassium cyanate
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

benzoyl chloride
98-88-4

benzoyl chloride

1-(3-benzoylamino-butyl)-4-benzoyloxy-benzene

1-(3-benzoylamino-butyl)-4-benzoyloxy-benzene

Conditions
ConditionsYield
With sodium hydroxide
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

2-cyclopenten-1-yl chloride
96-40-2

2-cyclopenten-1-yl chloride

optically inactive 4-(3-cyclopent-2-enylamino-butyl)-phenol

optically inactive 4-(3-cyclopent-2-enylamino-butyl)-phenol

Conditions
ConditionsYield
With 1,4-dioxane
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

allyl bromide
106-95-6

allyl bromide

4-(3-Allylamino-butyl)-phenol

4-(3-Allylamino-butyl)-phenol

Conditions
ConditionsYield
With benzene
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

cyclopentanone
120-92-3

cyclopentanone

4-(3-Cyclopentylamino-butyl)-phenol

4-(3-Cyclopentylamino-butyl)-phenol

Conditions
ConditionsYield
With methanol; platinum Hydrogenation;
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

1-bromo-butene-(2t)

1-bromo-butene-(2t)

4-[3-(buten-(2t)-ylamino)-butyl]-phenol

4-[3-(buten-(2t)-ylamino)-butyl]-phenol

Conditions
ConditionsYield
With benzene
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

2,4,6-triphenylpyrylium tetrafluoroborate
448-61-3

2,4,6-triphenylpyrylium tetrafluoroborate

6-(4-hydroxyphenyl)-4-methyl-1,1-diphenylhex-1-en-3-one

6-(4-hydroxyphenyl)-4-methyl-1,1-diphenylhex-1-en-3-one

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: acetic acid / dichloromethane / 20 °C
1.2: 6 h / 20 °C
2.1: lithium methanolate; 1,8-diazabicyclo[5.4.0]undec-7-ene / tetrahydrofuran / 15 h / 80 °C / 37503.8 Torr / Autoclave; Sealed tube
View Scheme
p-hydroxyhomoamphetamine
52846-75-0

p-hydroxyhomoamphetamine

methyl 2-(di-(tert-butoxycarbonyl)amino)-6-(4-hydroxyphenyl)-4-methylhexanoate

methyl 2-(di-(tert-butoxycarbonyl)amino)-6-(4-hydroxyphenyl)-4-methylhexanoate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ethanol / 4 h / 80 - 85 °C
2: diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate / dimethyl sulfoxide; water / 20 h / 20 °C / Schlenk technique; Sealed tube; Irradiation
View Scheme

52846-75-0Relevant academic research and scientific papers

8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study

Xing, Gang,Zhi, Zhengxing,Yi, Ce,Zou, Jitian,Jing, Xuefeng,Yiu-Ho Woo, Anthony,Lin, Bin,Pan, Li,Zhang, Yuyang,Cheng, Maosheng

, (2021/07/19)

β2-Agonists that bind to plasmalemmal β2-adrenoceptors causing cAMP accumulation are widely used as bronchodilators in chronic respiratory diseases. Here, we designed and synthesized a group of 8-hydroxyquinolin-2(1H)-one analogues and studied their β2-agonistic activities with a cellular cAMP assay. Compounds B05 and C08 were identified as potent (EC50 2-agonists among the compounds tested. They behaved as partial β2-agonists in non-overexpressed HEK293 cells, and possessed rapid smooth muscle relaxant actions and long duration of action in isolated guinea pig tracheal strip preparations. In summary, B05 and C08 are β2-agonists with potential applicability in chronic respiratory diseases.

General and selective synthesis of primary amines using Ni-based homogeneous catalysts

Beller, Matthias,Chandrashekhar, Vishwas G.,Jagadeesh, Rajenahally V.,Jiao, Haijun,Murugesan, Kathiravan,Wei, Zhihong

, p. 4332 - 4339 (2020/05/18)

The development of base metal catalysts for industrially relevant amination and hydrogenation reactions by applying abundant and atom economical reagents continues to be important for the cost-effective and sustainable synthesis of amines which represent highly essential chemicals. In particular, the synthesis of primary amines is of central importance because these compounds serve as key precursors and central intermediates to produce value-added fine and bulk chemicals as well as pharmaceuticals, agrochemicals and materials. Here we report a Ni-triphos complex as the first Ni-based homogeneous catalyst for both reductive amination of carbonyl compounds with ammonia and hydrogenation of nitroarenes to prepare all kinds of primary amines. Remarkably, this Ni-complex enabled the synthesis of functionalized and structurally diverse benzylic, heterocyclic and aliphatic linear and branched primary amines as well as aromatic primary amines starting from inexpensive and easily accessible carbonyl compounds (aldehydes and ketones) and nitroarenes using ammonia and molecular hydrogen. This Ni-catalyzed reductive amination methodology has been applied for the amination of more complex pharmaceuticals and steroid derivatives. Detailed DFT computations have been performed for the Ni-triphos based reductive amination reaction, and they revealed that the overall reaction has an inner-sphere mechanism with H2metathesis as the rate-determining step.

MOF-derived cobalt nanoparticles catalyze a general synthesis of amines

Jagadeesh, Rajenahally V.,Murugesan, Kathiravan,Alshammari, Ahmad S.,Neumann, Helfried,Pohl, Marga-Martina,Radnik, J?rg,Beller, Matthias

, p. 326 - 332 (2017/09/28)

The development of base metal catalysts for the synthesis of pharmaceutically relevant compounds remains an important goal of chemical research. Here, we report that cobalt nanoparticles encapsulated by a graphitic shell are broadly effective reductive amination catalysts. Their convenient and practical preparation entailed template assembly of cobaltdiamine- dicarboxylic acid metal organic frameworks on carbon and subsequent pyrolysis under inert atmosphere.The resulting stable and reusable catalysts were active for synthesis of primary, secondary, tertiary, and N-methylamines (more than 140 examples).The reaction couples easily accessible carbonyl compounds (aldehydes and ketones) with ammonia, amines, or nitro compounds, and molecular hydrogen under industrially viable and scalable conditions, offering cost-effective access to numerous amines, amino acid derivatives, and more complex drug targets.

Derivatives related to betaxolol with α- and β-adrenergic activities

Leclerc,Decker,Schwartz

, p. 1357 - 1367 (2007/10/02)

The paper describes the synthesis and the pharmacological evaluation of some derivatives of betaxolol, all with an N-aralkylamine instead of the tertiobutylamine. These compounds have been tested for β1-adrenergic receptor antagonism on guinea pig atria, β2-adrenergic receptor antagonism on guinea pig trachea and α-adrenergic blocking activity on rat aorta. Compound U12 with a marked α-blocking activity and compound R8 with a β1/α ratio = 1 were selected for a haemodynamic study in the dog. The decrease in cardiac work and the diminution of total peripheral resistance exhibited by U12 are consistent with a dual α/β-blocking agent. Finally, structure-activity relationships are discussed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 52846-75-0